SCHEMBL4992967

SCHEMBL4992967

O=C(O)CNC(=O)c1c(O)nc(-c2c(Cl)cccc2Cl)n(C2CCCCC2)c1=O

nearest known ligand 0.57

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
EGLN3 Q9H6Z9 2/20 0.57
EGLN1 Q9GZT9 5/20 0.53
OGFOD1 Q8N543 1/20 0.53
EGLN2 Q96KS0 1/20 0.53
HIF1AN Q9NWT6 1/20 0.53
OGFRL1 Q5TC84 3/20 0.39
DPP4 P27487 1/20 0.39
PREP P48147 1/20 0.39
FAP Q12884 1/20 0.39
OPRM1 P35372 2/20 0.38
OPRD1 P41143 2/20 0.38
OPRK1 P41145 2/20 0.38
HIF1A Q16665 1/20 0.37
CYP2C19 P33261 1/20 0.37
MAPT P10636 1/20 0.37
MEN1 O00255 1/20 0.37
ALDH1A1 P00352 1/20 0.37
GAA P10253 1/20 0.37
KMT2A Q03164 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4988651 0.88 EGLN1 (0.53) EGLN3EGLN1OGFOD1EGLN2HIF1AN
SCHEMBL4997472 0.86 EGLN1 (0.57) EGLN3EGLN1OGFOD1EGLN2HIF1AN
SCHEMBL4993693 0.82 EGLN1 (0.63) EGLN3EGLN1OGFOD1EGLN2HIF1AN
SCHEMBL4994572 0.80 EGLN3 (0.66) EGLN3EGLN1EGLN2HIF1ACYP2C19
SCHEMBL4988775 0.80 EGLN1 (0.53) EGLN3EGLN1OGFOD1EGLN2HIF1AN
SCHEMBL4737673 0.79 EGLN1 (0.65) EGLN3EGLN1OGFOD1EGLN2HIF1AN
SCHEMBL4740495 0.79 EGLN1 (0.65) EGLN3EGLN1OGFOD1EGLN2HIF1AN
SCHEMBL4988793 0.78 EGLN3 (0.46) EGLN3EGLN1OGFOD1EGLN2HIF1AN
SCHEMBL4996354 0.78 EGLN3 (0.80) EGLN3EGLN1EGLN2
SCHEMBL4991742 0.77 EGLN1 (0.54) EGLN3EGLN1OGFOD1EGLN2HIF1AN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080171756-A1 N-Substituted Glycine Derivatives: Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2008-07-17 US claimed
WO-2008089051-A1 N-SUBSTITUTED GLYCINE DERIVATIVES: PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2008-07-24 WO disclosed
US-20080171756-A1 N-Substituted Glycine Derivatives: Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2008-07-17 US disclosed
US-20080171756-A1 N-Substituted Glycine Derivatives: Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2008-07-17 US disclosed
US-20080171756-A1 N-Substituted Glycine Derivatives: Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2008-07-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080171756-A1 N-Substituted Glycine Derivatives: Prolyl Hydroxylase Inhibitors HIF1AN, EGLN2, EGLN3 EGLN3 3/4885EGLN1 5/4885OGFOD1 15/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.